Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 4.76 1.28% 0.06
TGTX closed up 1.28 percent on Friday, February 15, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical TGTX trend table...

Date Alert Name Type % Chg
Feb 15 Spinning Top Other 0.00%
Feb 15 NR7 Range Contraction 0.00%
Feb 15 NR7-2 Range Contraction 0.00%
Feb 15 Weak + Overbought Other 0.00%
Feb 15 Weak, Overbought and Reversal Signs Reversal 0.00%
Feb 15 Above Upper BB Strength 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 15 Up 3 Days in a Row Strength 0.00%
Feb 15 Up 4 Days in a Row Strength 0.00%
Feb 15 Up 5 Days in a Row Strength 0.00%

Older signals for TGTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
Is TGTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.35
52 Week Low 3.32
Average Volume 1,397,664
200-Day Moving Average 8.7359
50-Day Moving Average 4.41
20-Day Moving Average 4.2975
10-Day Moving Average 4.361
Average True Range 0.2542
ADX 15.63
+DI 29.0916
-DI 13.7403
Chandelier Exit (Long, 3 ATRs ) 4.2374
Chandelier Exit (Short, 3 ATRs ) 4.6326
Upper Bollinger Band 4.762
Lower Bollinger Band 3.833
Percent B (%b) 1.0
BandWidth 21.617219
MACD Line 0.0412
MACD Signal Line -0.0404
MACD Histogram 0.0816
Fundamentals Value
Market Cap 296.6 Million
Num Shares 62.3 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -2.44
Price-to-Sales 3189.49
Price-to-Book 6.24
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.00
Resistance 3 (R3) 4.99 4.91 4.96
Resistance 2 (R2) 4.91 4.85 4.91 4.95
Resistance 1 (R1) 4.83 4.81 4.87 4.84 4.93
Pivot Point 4.75 4.75 4.77 4.75 4.75
Support 1 (S1) 4.67 4.69 4.71 4.68 4.59
Support 2 (S2) 4.59 4.65 4.59 4.57
Support 3 (S3) 4.51 4.59 4.56
Support 4 (S4) 4.52